This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi must face trimmed US antitrust case over injectable insulin

( January 27, 2026, 16:47 GMT | Official Statement) -- MLex Summary: Sanofi-Aventis must face some of Mylan’s US antitrust claims over an injectable form of diabetes drug insulin glargine, according to a federal judge. District Judge Mark R. Hornak denied in-part Sanofi’s motion to dismiss, concluding that the complaint adequately alleges that Sanofi has monopoly power in the market for injectable insulin glargine and that it has maintained this monopoly through exclusionary conduct. Hornak dismissed Mylan’s allegation of a violation based solely on a “product hop” theory.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections